Tonix strives for pandemic readiness with new US manufacturing facility

The company's goal is to design and test new vaccines for novel pathogens within 100 days of a potential pandemic threat
Vaccines for monkeypox, smallpox and COVID-19 are among some of the products that will be developed by Tonix Pharmaceuticals at its new clinical-scale manufacturing facility in North Dartmouth, Massachusetts.
The clinical-stage biopharma company officially launched its Advanced Development Center (ADC) with a ribbon cutting ceremony on Tuesday. Tonix plans to develop vaccines against infectious diseases at the new facility using its recombinant pox virus platform technology, which it says is ‘rapidly deployable for addressing potential novel or emerging pathogens.’
The 45,000 sq ft facility features single-use bioreactors and purification suites with equipment for GMP production of vaccines for clinical trials, including the capability to produce sterile vaccines in glass bottles. It has been designated a Biosafety Level 2 site, a Centers for Disease Control and Prevention label which means the microbes there pose moderate hazards to laboratorians and the environment.
According to Tonix Pharmaceuticals CEO Seth Lederman, the facility will accelerate development of vaccines targeting infectious diseases.
He commented: ‘The ADC greatly enhances our ability to progress our pipeline of vaccines for infectious diseases, including monkeypox, smallpox and COVID-19. We believe that the recombinant pox virus platform technology underlying our key vaccines in development, TNX-801, TNX-1840 and TNX-1850, coupled with our capabilities at the Tonix R&D Center (RDC) for research and development, will be rapidly deployable for addressing potential novel or emerging pathogens, with simplified distribution and administration, relative to modified mRNA-based vaccines.’
Lederman said the company’s goal is to ‘be able to design and test new recombinant pox virus vaccines against novel pathogens within the 100 days of recognition of a potential emerging pandemic threat’, noting that this timeline meets criteria set out by the White House Office of Science and Technology Policy.
Tonix’s portfolio features a range of investigational new drugs or biologics that are progressing through clinical trials. These include TNX-102 SL, a candidate in mid-Phase 3 development for the management of fibromyalgia, and TNX-102 SL, which is being developed to treat Long COVID.
Related News
-
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: -
News Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities. -
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance